Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Amphotericin B Liposome vs AmBisome in Healthy Subjects
NCT04993222Phase 1Completed
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liposomal amphotericin b in invasive fungal infection (IFI) (2 arms), sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 674 hours, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration up to 674 hours and 1 more. Started Jun 2020; status: completed.
02
Drugs
liposomal amphotericin b
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT04993222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04993222.